Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia

J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):342-345. doi: 10.1093/jpids/pix084.

Abstract

We report here the first pharmacokinetic-pharmacodynamic relationship for ceftaroline in a preterm infant born at <28 weeks' gestational age who was given ceftaroline (8.5 mg/kg every 8 hours) for pneumonia attributable to methicillin-resistant Staphyloccocus aureus. This dose of ceftaroline was adequate to achieve the pharmacodynamic endpoint associated with efficacy for methicillin-resistant Staphyloccocus aureus.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics*
  • Ceftaroline
  • Cephalosporins / administration & dosage
  • Cephalosporins / pharmacokinetics*
  • Drug Therapy, Combination
  • Fatal Outcome
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / blood
  • Infant, Premature, Diseases / drug therapy*
  • Infant, Premature, Diseases / microbiology
  • Methicillin-Resistant Staphylococcus aureus* / drug effects
  • Pneumonia, Staphylococcal / blood
  • Pneumonia, Staphylococcal / drug therapy*
  • Pneumonia, Staphylococcal / microbiology
  • Rifampin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Rifampin